SBTX Stock Overview
A life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SkinBioTherapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.16 |
| 52 Week High | UK£0.20 |
| 52 Week Low | UK£0.07 |
| Beta | 1.75 |
| 11 Month Change | -1.55% |
| 3 Month Change | 27.00% |
| 1 Year Change | -14.77% |
| 33 Year Change | -60.80% |
| 5 Year Change | 9.48% |
| Change since IPO | 19.81% |
Recent News & Updates
Recent updates
Here's Why We're Watching SkinBioTherapeutics' (LON:SBTX) Cash Burn Situation
Mar 28
Will SkinBioTherapeutics (LON:SBTX) Spend Its Cash Wisely?
Sep 30Is SkinBioTherapeutics (LON:SBTX) In A Good Position To Deliver On Growth Plans?
Jun 11We Think SkinBioTherapeutics (LON:SBTX) Can Afford To Drive Business Growth
Feb 16We're Not Worried About SkinBioTherapeutics' (LON:SBTX) Cash Burn
Sep 29Companies Like SkinBioTherapeutics (LON:SBTX) Can Afford To Invest In Growth
Mar 23How Much Are SkinBioTherapeutics Plc (LON:SBTX) Insiders Taking Off The Table?
Jan 29Companies Like SkinBioTherapeutics (LON:SBTX) Are In A Position To Invest In Growth
Dec 07
Shareholder Returns
| SBTX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.6% | 1.5% | 2.2% |
| 1Y | -14.8% | -17.9% | 8.8% |
Return vs Industry: SBTX exceeded the UK Biotechs industry which returned -17.9% over the past year.
Return vs Market: SBTX underperformed the UK Market which returned 8.8% over the past year.
Price Volatility
| SBTX volatility | |
|---|---|
| SBTX Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SBTX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: SBTX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 11 | Stuart Ashman | www.skinbiotherapeutics.com |
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
SkinBioTherapeutics plc Fundamentals Summary
| SBTX fundamental statistics | |
|---|---|
| Market cap | UK£36.26m |
| Earnings (TTM) | -UK£2.88m |
| Revenue (TTM) | UK£161.65k |
224.3x
P/S Ratio-12.6x
P/E RatioIs SBTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBTX income statement (TTM) | |
|---|---|
| Revenue | UK£161.65k |
| Cost of Revenue | UK£59.97k |
| Gross Profit | UK£101.68k |
| Other Expenses | UK£2.99m |
| Earnings | -UK£2.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 62.90% |
| Net Profit Margin | -1,784.72% |
| Debt/Equity Ratio | 0% |
How did SBTX perform over the long term?
See historical performance and comparison